Ad-hoc RELEASE

Announcement according to Article 17 European Market Abuse Regulation (MAR)

 

Increase of the EBIT guidance

 

Dreieich, 05 October 2023. Against the background of the agreements concluded between Biotest AG, Dreieich, Germany and Grifols, S.A., Barcelona, Spain, which include a technology transfer and licensing agreement, the Management Board of Biotest AG had forcasted in April 2023 an EBIT that may possibly exceed € 100 million. Based on current information, the Executive Board expects EBIT for fiscal 2023 to be in the order of
€ 130 - 170 million. A more precise determination depends on the revenue and earnings realisation of the final project milestones.

 

The Executive Board continues to aim for a mid-single-digit percentage increase in revenue for the 2023 financial year compared to 2022, excluding revenue from the technology transfer and licensing agreement. This increase in sales is possible due to the commissioning of the Yimmugo^® production facility within Biotest Next Level. The Management Board does not rule out the possibility of negative sales influences as a result of possible declines in demand due to the economic situation and country-specific savings in the healthcare sector.

 

 

Biotest Aktiengesellschaft
Board of Management

 

Biotest AG

Landsteinerstr. 5

D-63303 Dreieich

www.biotest.com

 

 

Disclaimer

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

 

 

About Biotest

Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 2,300 employees worldwide. The preference shares of Biotest AG are listed in the Prime Standard on the Frankfurt stock exchange.

 

 

 

IR contact

Dr. Monika Buttkereit

phone: +49-6103-801-4406
email: [email protected]

 

PR contact

Dirk Neumüller

phone: +49-6103-801-269
email: [email protected]

 

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

 

Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201

Preference shares: securities’ ID No. 522723; ISIN DE0005227235

Listing: Frankfurt (Prime Standard)

Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

Contact:
Dr. Michael Ramroth
CEO
Biotest AG
Landsteinerstr. 5
63303 Dreieich
Tel. +40 6103 801 225
Fax: +49 6103 801 347
[email protected]